Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 10/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | JAK2 | O60674 | 4/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 2/20 | 0.35 |
| ▸ | PLK4 | O00444 | 2/20 | 0.35 |
| ▸ | MARK3 | P27448 | 2/20 | 0.35 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.35 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.35 |
| ▸ | STK3 | Q13188 | 2/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.35 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.35 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.35 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1496087 | 0.92 | CHEK1 (0.43) | CHEK1KCNH2JAK2LRRK2FLT1 | |
| SCHEMBL1496167 | 0.89 | CHEK1 (0.45) | CHEK1JAK2FLT1KDR | |
| SCHEMBL1496049 | 0.89 | CHEK1 (0.39) | CHEK1KCNH2FLT1KDREGFR | |
| SCHEMBL1496086 | 0.86 | CHEK1 (0.53) | CHEK1KDRMEN1NPC1GAA | |
| SCHEMBL1495993 | 0.86 | CHEK1 (0.43) | CHEK1LRRK2FLT1DAPK3PIM1 | |
| SCHEMBL1496012 | 0.79 | CHEK1 (0.44) | CHEK1KCNH2JAK2LRRK2FLT1 | |
| SCHEMBL1496017 | 0.78 | CHEK1 (0.43) | CHEK1KCNH2JAK2LRRK2FLT1 | |
| SCHEMBL1496157 | 0.77 | JAK2 (0.49) | CHEK1KCNH2JAK2LRRK2FLT1 | |
| SCHEMBL1496102 | 0.77 | CHEK1 (0.44) | CHEK1KCNH2JAK2LRRK2FLT1 | |
| SCHEMBL1496121 | 0.77 | CHEK1 (0.45) | CHEK1KCNH2JAK2LRRK2FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240009190-A1 | COMBINATION CANCER THERAPY USING CHK INHIBITOR | Shanghai Huayu Biotechnology Co., Ltd. (CN) | 2024-01-11 | — | — | US | claimed |
| US-20230049029-A1 | COMBINATION CANCER THERAPY USING CHK INHIBITOR | Shanghai Huayu Biotechnology Co., Ltd. (CN) | 2023-02-16 | — | — | US | claimed |
| US-20150072987-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | SHANGHAI HUAYU BIOTECH CO., LTD (CN) | 2015-03-12 | — | — | US | claimed |
| US-8815863-B2 | Compounds and therapeutic use thereof for protein kinase inhibition | SHANGHAI HUAYU BIOTECH CO., LTD. (CN) | 2014-08-26 | — | — | US | claimed |
| US-20120232082-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | SHANGHAI HUAYU BIOTECH CO., LTD. (CN) | 2012-09-13 | — | — | US | claimed |
| US-20240009190-A1 | COMBINATION CANCER THERAPY USING CHK INHIBITOR | Shanghai Huayu Biotechnology Co., Ltd. (CN) | 2024-01-11 | — | — | US | disclosed |
| US-20230049029-A1 | COMBINATION CANCER THERAPY USING CHK INHIBITOR | Shanghai Huayu Biotechnology Co., Ltd. (CN) | 2023-02-16 | — | — | US | disclosed |
| WO-2021141980-A1 | COMBINATION CANCER THERAPY USING CHK INHIBITOR | WU FAN (US) | 2021-07-15 | — | — | WO | disclosed |
| WO-2021141974-A2 | COMBINATION CANCER THERAPY USING CHK INHIBITOR | WU FAN (US) | 2021-07-15 | — | — | WO | disclosed |
| US-9487539-B2 | Compounds and therapeutic use thereof for protein kinase inhibition | SHANGHAI HUAYU BIOTECH CO., LTD (CN) | 2016-11-08 | — | — | US | disclosed |
| EP-2826780-B1 | Thieno[2,3-d]pyridazine derivatives and therapeutic use thereof for protein kinase inhibition | WU ZHANGGUI (US) | 2016-06-01 | — | — | EP | disclosed |
| US-20150072987-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | SHANGHAI HUAYU BIOTECH CO., LTD (CN) | 2015-03-12 | — | — | US | disclosed |
| EP-2826780-A1 | Thieno[2,3-d]pyridazine derivatives and therapeutic use thereof for protein kinase inhibition | Wu, Zhanggui (US) | 2015-01-21 | — | — | EP | disclosed |
| US-8815863-B2 | Compounds and therapeutic use thereof for protein kinase inhibition | SHANGHAI HUAYU BIOTECH CO., LTD. (CN) | 2014-08-26 | — | — | US | disclosed |
| EP-2477496-B1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | WU ZHANGGUI (US) | 2014-04-16 | — | — | EP | disclosed |
| US-20120232082-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | SHANGHAI HUAYU BIOTECH CO., LTD. (CN) | 2012-09-13 | — | — | US | disclosed |
| EP-2477496-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | Wu, Zhanggui (US) | 2012-07-25 | — | — | EP | disclosed |
| WO-2011035077-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | WU ZHANGGUI (US) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230049029-A1 | COMBINATION CANCER THERAPY USING CHK INHIBITOR | CHEK1, DCK, CHEK2 | CHEK1 1/4885KCNH2 4446/4885JAK2 1341/4885 |
| US-20240009190-A1 | COMBINATION CANCER THERAPY USING CHK INHIBITOR | CHEK1, CHEK2, DCK | CHEK1 1/4885KCNH2 4526/4885JAK2 1101/4885 |
| US-20150072987-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | CHEK2, CHEK1, PLK1 | CHEK1 2/4885KCNH2 4177/4885JAK2 839/4885 |
| US-20120232082-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | CHEK2, CHEK1, BUB1B | CHEK1 2/4885KCNH2 4004/4885JAK2 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.